EVKIF
Evonik Industries AG
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
21.52
▲ 0.22 (1.03%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
21.30
Day high
17.00
Day low
17.00
Volume
1.00K
Market cap
—
P/E (TTM)
—
52W range
14.49 – 21.52
Trailing performance
Returnvs SPY
1W
+2.63%
+3.8%
1M
+15.02%
+11.7%
3M
+1.03%
-1.4%
6M
+17.92%
+6.0%
YTD
+39.63%
+27.7%
1Y
+11.16%
-9.0%
3Y
+13.26%
-61.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on EVKIF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $14.07B | $15.16B | $15.27B | $18.49B | -7.2% |
| Operating revenue | $14.07B | $15.16B | $15.27B | $18.49B | -7.2% |
| Cost of revenue | $10.82B | $11.42B | $12.57B | $14.26B | -5.2% |
| Gross profit | $3.24B | $3.74B | $2.70B | $4.23B | -13.2% |
| Research & development | $418.00M | $459.00M | $443.00M | $460.00M | -8.9% |
| Selling, general & admin | $2.21B | $2.67B | $2.33B | $2.62B | -17.2% |
| Total operating expense | $2.60B | $3.10B | $2.80B | $2.97B | -16.0% |
| Operating income | $641.00M | $639.00M | -$99.00M | $1.26B | +0.3% |
| Net interest income | -$135.00M | -$127.00M | -$89.00M | $0 | -6.3% |
| Pre-tax income | $422.00M | $434.00M | -$351.00M | $923.00M | -2.8% |
| Tax provision | $145.00M | $194.00M | $101.00M | $369.00M | -25.3% |
| Net income | $265.00M | $222.00M | -$465.00M | $540.00M | +19.4% |
| Net income to common | $265.00M | $222.00M | -$465.00M | $540.00M | +19.4% |
| Basic EPS | 0.57 | 0.48 | -1.00 | 1.16 | +18.7% |
| Diluted EPS | 0.57 | 0.48 | -1.00 | 1.16 | +18.7% |
| EBIT | $640.00M | $646.00M | -$107.00M | $1.04B | -0.9% |
| EBITDA | $1.84B | $1.76B | $1.73B | $2.61B | +4.5% |
| Basic shares | 466.00M | 466.00M | 466.00M | 466.00M | 0.0% |
| Diluted shares | 466.00M | 466.00M | 466.00M | 466.00M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $495.00M | $461.00M | $749.00M | $645.00M | +7.4% |
| Cash & short-term investments | $623.00M | $618.00M | $1.03B | $1.12B | +0.8% |
| Accounts receivable | $1.53B | $1.63B | $1.62B | $1.93B | -6.1% |
| Inventory | $2.30B | $2.66B | $2.35B | $2.82B | -13.6% |
| Total current assets | $4.97B | $5.51B | $5.90B | $6.66B | -9.8% |
| Property, plant & equipment | $6.90B | $7.40B | $7.26B | $7.93B | -6.7% |
| Goodwill & intangibles | $5.10B | $5.57B | $5.53B | $5.71B | -8.5% |
| Total assets | $17.98B | $19.75B | $19.94B | $21.81B | -9.0% |
| Total current liabilities | $3.33B | $4.06B | $4.05B | $3.65B | -18.0% |
| Current debt | $414.00M | $665.00M | $801.00M | $48.00M | -37.7% |
| Long-term debt | $2.59B | $2.20B | $2.53B | $3.23B | +17.9% |
| Total debt | $3.87B | $3.78B | $4.26B | $4.22B | +2.4% |
| Total liabilities | $9.81B | $10.65B | $10.95B | $10.75B | -7.9% |
| Retained earnings | $7.17B | $7.43B | $7.55B | $9.35B | -3.4% |
| Shareholder equity | $8.11B | $9.02B | $8.91B | $10.97B | -10.1% |
| Working capital | $1.64B | $1.45B | $1.86B | $3.02B | +13.1% |
| Net tangible assets | $3.01B | $3.45B | $3.38B | $5.26B | -12.6% |
| Shares issued | 466.00M | 466.00M | 466.00M | 466.00M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $578.00M | $577.00M | -$243.00M | $942.00M | +0.2% |
| Depreciation & amortisation | $1.20B | $1.12B | $1.84B | $1.57B | +7.7% |
| Change in working capital | -$241.00M | $204.00M | $214.00M | -$643.00M | -218.1% |
| Operating cash flow | $1.44B | $1.71B | $1.59B | $1.65B | -15.8% |
| Capital expenditure | -$748.00M | -$840.00M | -$793.00M | -$865.00M | +11.0% |
| Investing cash flow | -$652.00M | -$663.00M | -$653.00M | -$777.00M | +1.7% |
| Share buybacks | -$1.00M | -$12.00M | -$16.00M | -$16.00M | +91.7% |
| Dividends paid | -$545.00M | -$545.00M | -$545.00M | -$545.00M | 0.0% |
| Financing cash flow | -$731.00M | -$1.33B | -$823.00M | -$672.00M | +45.0% |
| Free cash flow | $695.00M | $873.00M | $801.00M | $785.00M | -20.4% |
| End cash position | $495.00M | $461.00M | $749.00M | $645.00M | +7.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.89B | $3.43B | $3.40B | $3.50B | $3.78B | +13.6% |
| Operating revenue | $3.89B | $3.43B | $3.40B | $3.50B | $3.78B | +13.6% |
| Cost of revenue | $2.93B | $2.56B | $2.71B | $2.57B | $2.77B | +14.4% |
| Gross profit | $962.00M | $864.00M | $689.00M | $931.00M | $1.01B | +11.3% |
| Research & development | $96.00M | $94.00M | $103.00M | $105.00M | $106.00M | +2.1% |
| Selling, general & admin | $590.00M | $533.00M | $544.00M | $559.00M | $580.00M | +10.7% |
| Total operating expense | $801.00M | $636.00M | $553.00M | $697.00M | $711.00M | +25.9% |
| Operating income | $161.00M | $228.00M | $136.00M | $234.00M | $297.00M | -29.4% |
| Net interest income | -$41.00M | -$46.00M | -$9.00M | -$44.00M | -$29.00M | +10.9% |
| Pre-tax income | $122.00M | $183.00M | $38.00M | $192.00M | $270.00M | -33.3% |
| Tax provision | $37.00M | $54.00M | $18.00M | $68.00M | $34.00M | -31.5% |
| Net income | $84.00M | $125.00M | $18.00M | $120.00M | $233.00M | -32.8% |
| Net income to common | $84.00M | $125.00M | $18.00M | $120.00M | $233.00M | -32.8% |
| Basic EPS | 0.18 | 0.27 | — | 0.26 | 0.50 | -33.3% |
| Diluted EPS | 0.18 | 0.27 | — | 0.26 | 0.50 | -33.3% |
| EBIT | $177.00M | $234.00M | $92.00M | $248.00M | $321.00M | -24.4% |
| EBITDA | $553.00M | $473.00M | $367.00M | $508.00M | $561.00M | +16.9% |
| Basic shares | 466.67M | 462.96M | — | — | 466.00M | +0.8% |
| Diluted shares | 466.67M | 462.96M | — | 461.54M | 466.00M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $390.00M | $589.00M | $495.00M | $379.00M | $733.00M | — | -33.8% |
| Cash & short-term investments | $587.00M | $801.00M | $623.00M | $846.00M | $1.31B | — | -26.7% |
| Accounts receivable | $1.89B | $1.73B | $1.53B | $1.63B | $1.73B | — | +9.1% |
| Inventory | $2.68B | $2.43B | $2.30B | $2.65B | $2.75B | — | +10.4% |
| Total current assets | $5.66B | $5.43B | $4.97B | $5.60B | $6.37B | — | +4.2% |
| Property, plant & equipment | $6.82B | $6.92B | $6.90B | $6.99B | $7.21B | — | -1.5% |
| Goodwill & intangibles | $5.12B | $5.12B | $5.10B | $5.18B | $5.43B | — | -0.1% |
| Total assets | $18.61B | $18.46B | $17.98B | $19.05B | $20.24B | — | +0.9% |
| Total current liabilities | $3.78B | $3.60B | $3.33B | $3.87B | $4.17B | — | +5.1% |
| Current debt | — | — | $414.00M | — | — | $665.00M | — |
| Long-term debt | — | — | $2.59B | — | — | $2.20B | — |
| Total debt | — | — | $3.87B | — | — | $3.78B | — |
| Total liabilities | $10.68B | $10.16B | $9.81B | $10.49B | $10.97B | — | +5.1% |
| Retained earnings | $6.82B | $7.21B | $7.17B | $7.50B | $7.84B | — | -5.4% |
| Shareholder equity | $7.87B | $8.23B | $8.11B | $8.49B | $9.19B | — | -4.3% |
| Working capital | $1.88B | $1.83B | $1.64B | $1.73B | $2.19B | — | +2.4% |
| Net tangible assets | $2.76B | $3.11B | $3.01B | $3.32B | $3.76B | — | -11.3% |
| Shares issued | 466.00M | 466.00M | 466.00M | 466.00M | 466.00M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $163.00M | $229.00M | $68.00M | $236.00M | $299.00M | — | -28.8% |
| Depreciation & amortisation | $376.00M | $239.00M | $275.00M | $260.00M | $240.00M | — | +57.3% |
| Change in working capital | -$299.00M | -$35.00M | $339.00M | -$513.00M | -$165.00M | — | -754.3% |
| Operating cash flow | $229.00M | $407.00M | $612.00M | -$35.00M | $385.00M | — | -43.7% |
| Capital expenditure | -$180.00M | -$224.00M | -$201.00M | -$176.00M | -$190.00M | — | +19.6% |
| Investing cash flow | -$161.00M | -$203.00M | -$169.00M | $34.00M | -$511.00M | — | +20.7% |
| Share buybacks | $0 | — | $0 | -$1.00M | $0 | $0 | — |
| Dividends paid | -$466.00M | — | $0 | -$545.00M | — | $0 | — |
| Financing cash flow | -$270.00M | -$112.00M | -$400.00M | -$341.00M | $402.00M | — | -141.1% |
| Free cash flow | $49.00M | $183.00M | $411.00M | -$211.00M | $195.00M | — | -73.2% |
| End cash position | $390.00M | $589.00M | $495.00M | $379.00M | $733.00M | — | -33.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
20.99
+2.54% from price
SMA 20
19.94
+7.90% from price
SMA 50
19.15
+12.36% from price
SMA 100
19.72
+9.14% from price
SMA 200
17.85
+20.54% from price
EMA 12
20.74
+3.77% from price
EMA 26
20.13
+6.91% from price
EMA 50
19.73
+9.07% from price
RSI (14)
85.0
Overbought
MACD (12,26,9)
0.61
Hist 0.16
ATR (14)
0.20
0.93% of price
Realised vol 30D
35.6%
Annualised
Bollinger upper
22.22
20, 2σ
Bollinger lower
17.67
20, 2σ
50 / 200 cross
Golden
19.15 vs 17.85
Trend bias
Above 200
+20.54%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.05
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
35.6%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-26.7%
Peak to trough
Max drawdown 5Y
-57.6%
Peak to trough
ATR 14
0.20
0.93% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Medical Plastics Market to Reach USD 48.77 billion by 2031, Growing at a CAGR of 7.0% — MarketsandMarkets™
GlobeNewswire · 6d ago
Jungbunzlauer appoints Marcus von Twistern as EVP Operations
PR Newswire · 22d ago
[Latest] Global Implantable Cardiac Fluorine-Free Resins Market Size/Share Worth USD 4.26 Billion by 2035 at a 10.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,SWOT Analysis)
GlobeNewswire · 33d ago
Global Glyceryl Glucoside Market to Reach USD 39.0 Million by 2031, Driven by Bio-Based Skincare Innovation
GlobeNewswire · 41d ago
Wax Market Size to Skyrocket USD 16.65 Billion by 2035 as Demand Grows Across Packaging, Cosmetics and Industrial Applications | SNS Insider
GlobeNewswire · 45d ago
Hydrophobic Fumed Silica Predicted as Fastest-Growing Segment Driven by Water-Resistance.
GlobeNewswire · 55d ago
[Latest] Global Bioprocess Digital Twin Market Size/Share Worth USD 6.47 Billion by 2035 at a 19.6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
GlobeNewswire · 60d ago
Bio-Based Cosmetics and Personal Care Ingredients Market Size/Share Worth USD 18.93 Billion by 2035 at a 11.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT)
GlobeNewswire · 70d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.